Jazz Pharmaceuticals plc [JAZZ] stock prices are up 0.73% to $109.78 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The JAZZ shares have gain 5.99% over the last week, with a monthly amount glided 6.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jazz Pharmaceuticals plc [NASDAQ: JAZZ] stock has seen the most recent analyst activity on March 07, 2025, when UBS upgraded its rating to a Buy and also boosted its price target to $179 from $145. Previously, Cantor Fitzgerald downgraded its rating to Neutral on February 26, 2025. On February 13, 2025, upgrade upgraded it’s rating to Overweight and revised its price target to $170 on the stock. Morgan Stanley upgraded its rating to a Overweight and increased its price target to $175 on December 12, 2024. Goldman initiated its recommendation with a Buy and recommended $169 as its price target on June 05, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on January 03, 2024, and assigned it a price target of $160. In a note dated November 27, 2023, UBS downgraded an Neutral rating on this stock and revised its target price from $170 to $135.
The stock price of Jazz Pharmaceuticals plc [JAZZ] has been fluctuating between $95.49 and $148.06 over the past year. Currently, Wall Street analysts expect the stock to reach $196.67 within the next 12 months. Jazz Pharmaceuticals plc [NASDAQ: JAZZ] shares were valued at $109.78 at the most recent close of the market. An investor can expect a potential return of 79.15% based on the average JAZZ price forecast.
Analyzing the JAZZ fundamentals
The Jazz Pharmaceuticals plc [NASDAQ:JAZZ] reported sales of 4.06B for trailing twelve months, representing a drop of -0.46%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.15%, Pretax Profit Margin comes in at 0.09%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.12 and Total Capital is 0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Jazz Pharmaceuticals plc [NASDAQ:JAZZ]’s Current Ratio is 3.38. On the other hand, the Quick Ratio is 2.97, and the Cash Ratio is 1.52. Considering the valuation of this stock, the price to sales ratio is 1.66, the price to book ratio is 1.62 and price to earnings (TTM) ratio is 14.80.
Transactions by insiders
Recent insider trading involved Mulligan Seamus, Director, that happened on May 09 ’25 when 100000.0 shares were purchased. Director, Mulligan Seamus completed a deal on May 12 ’25 to buy 1621.0 shares. Meanwhile, Chairman & CEO COZADD BRUCE C sold 1000.0 shares on May 01 ’25.
